NURECA LIMITED Intrinsic Value
NURECA · Healthcare · Current price ₹332.2
Is NURECA LIMITED undervalued?
DocStoX estimates the fair value of NURECA LIMITED at ₹149 per share, versus the current market price of ₹332. That puts the stock about -55.2% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is medium.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹164), Relative P/E (₹148), Graham floor (₹96). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹96 (bear) to ₹149 (base) to ₹171 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹332 versus an intrinsic value of ₹149, NURECA LIMITED currently offers -55.2% of negative margin (i.e. a premium).
More on NURECA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.